Stratasys Creates 3...
Health Care: Drugs
Merrimack Pharmaceuticals Inc (MACK: NASDAQ)
$5.26 0.15 | 2.94%
05/23/13 - 12:21 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | ||
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 37.71M | 50.45M | 30.71M | |
| Receivables | 9.27M | 7.43M | 3.74M | |
| Inventories | 0.00 | 0.00 | 0.00 | |
| Other Current Assets | 0.00 | 0.00 | 0.00 | |
| Total Current Assets | 128.30M | 65.59M | 36.29M | |
| Property, Plant & Equipment, Gross | 25.27M | 22.34M | 18.58M | |
| Accumulated Depreciation & Depletion | 18.97M | 16.13M | 11.12M | |
| Property, Plant & Equipment, Net | 6.30M | 6.21M | 7.46M | |
| Intangibles | 9.18M | 9.50M | 9.82M | |
| Other Non-Current Assets | 1.60M | 404.00K | 411.00K | |
| Total Non-Current Assets | 20.67M | 19.71M | 21.29M | |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 148.97M | 85.30M | 57.58M | |
| Accounts Payable | 283.00K | 4.66M | 1.44M | |
| Short Term Debt | 2.37M | 48.00K | 443.00K | |
| Other Current Liabilities | 1.08M | 0.00 | 0.00 | |
| Total Current Liabilities | 38.52M | 26.15M | 16.32M | |
| Long Term Debt | 37.48M | 0.00 | 0.00 | |
| Deferred Income Taxes | 755.00K | 1.27M | 810.00K | |
| Other Non-Current Liabilities | 78.64M | 79.57M | 68.07M | |
| Minority Interest | -477.00K | -453.00K | -55.00K | |
| Total Non-Current Liabilities | 116.97M | 349.64M | 261.22M | |
| Total Liabilities | 155.49M | 375.79M | 277.54M | |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | |
| Common Stock Equity | -6.52M | -290.49M | -219.96M | |
| Common Par | 958.00K | 118.00K | 111.00K | |
| Additional Paid In Capital | 434.68M | 60.23M | 45.10M | |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | |
| Retained Earnings | -442.12M | -350.84M | -271.62M | |
| Treasury Stock | 0.00 | 0.00 | 0.00 | |
| Other Equity Adjustments | -38.00K | 0.00 | 6.44M | |
| Total Capitalization | 30.96M | -290.49M | -219.96M | |
| Total Equity | -6.52M | -290.49M | -219.96M | |
| Total Liabilities & Stock Equity | 148.97M | 85.30M | 57.58M | |
| Total Common Shares Outstanding | 95.82M | 92.40M | 92.40M | |
| Preferred Shares | 0.00 | 0.00 | 0.00 | |
| Treasury Shares | 0.00 | 0.00 | 0.00 | |
| Basic Weighted Shares Outstanding | 72.83M | 11.34M | 0.00 | |
| Diluted Weighted Shares Outstanding | 72.83M | 11.34M | 0.00 | |
| Number of Employees | 230 | 218 | NA | |
| Number of Part-Time Employees | 0 | 0 | NA | |
Portfolios with MACK
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks With Big Insider Buy...
- ProTPG-Axon Capital
- ContributorStocks With Big Insider Buy...
- ContributorBreakout Stocks Of The Week...
Latest MACK Headlines from TheStreet
- Merrimack Pharmaceuticals Completes Enrollment In A Phase 2 Study Of MM-121 In Combination With Exemestane In Breast Cancer 05.23.13 | 08:05 am
- Merrimack Reports First Quarter 2013 Financial Results 05.13.13 | 10:05 am
- Merrimack To Present At Multiple Investor Conferences This Spring 05.02.13 | 08:05 am
- Merrimack Pharmaceuticals Announces Timing Of First Quarter 2013 Investor Conference Call 04.30.13 | 10:04 am
- Merrimack Pharmaceuticals Completes Enrollment Of Second Cohort In Phase 2 Study Of MM-121 In Non-Small Cell Lung Cancer 04.29.13 | 08:04 am
- Merrimack Pharmaceuticals Getting Very Oversold (MACK) 04.24.13 | 12:04 pm
- Merrimack Pharmaceuticals Completes Enrollment Of One Cohort In Neoadjuvant Phase 2 Study Of MM-121 In HER2-Negative Breast Cancer 04.15.13 | 08:04 am
- Merrimack Pharmaceuticals Announces Webcast Of Inaugural Research & Development Day 04.05.13 | 12:04 pm
- Merrimack Pharmaceuticals Completes Enrollment In A Phase 2 Study Of MM-121 In Combination With Paclitaxel In Patients With Platinum-Resistant Or Refractory Advanced Ovarian Cancers 03.18.13 | 08:03 am
- Merrimack Reports Fourth Quarter And Full Year 2012 Financial Results 03.14.13 | 08:03 am
Press Releases for MACK
- Merrimack Pharmaceuticals' Preclinical Research Shows MM-111 Restores Sensitivity To Chemotherapy And HER2-targeted Treatment In Gastric Cancer Model - PR Newswire 04.10.13 | 09:04 am
- Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor - PR Newswire 04.04.13 | 08:04 am
- Merrimack Pharmaceuticals To Present Preclinical Research On Five Novel Cancer Therapies - PR Newswire 04.02.13 | 09:04 am
- Merrimack Pharmaceuticals Presents Promising Phase I Clinical Data For Novel Agent To Treat HER2-positive Breast Cancer And Preclinical Data On Companion Diagnostic - PR Newswire 12.10.12 | 09:12 am
- Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer - PR Newswire 11.27.12 | 09:11 am
- Merrimack Pharmaceuticals' Therapies Show Promise In Certain Advanced Breast, Gastric And Gynecologic Cancers - PR Newswire 10.02.12 | 08:10 am
- Merrimack Pharmaceuticals To Present Preliminary Clinical Data For Novel Therapies Targeting Molecular Pathways In Advanced Cancers - PR Newswire 09.18.12 | 11:09 am
- Merrimack Pharmaceuticals, Inc. Announces Pricing Of Initial Public Offering - PR Newswire 03.28.12 | 11:03 pm
Partner Headlines for MACK
- After Hours Most Active for Nov 16, 2012 : SFD, QQQ, WIN, TSN, MSFT, TSS, BAC, MYL, ZGNX, WM, MACK, MMC - NASDAQ 11.16.12 | 09:11 pm
- Morning Market Losers - Benzinga 09.25.12 | 09:09 am
- 5 Low-Debt Biotech Stocks Forecasted For Growth - Seeking Alpha 09.22.12 | 09:09 am
- Jim Cramer Watchdog: SELL Morgan Stanley and 'BUY, BUY, BUY' These 3 HOT Stocks - Wall St. Cheat Sheet 07.20.12 | 11:07 am
